PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)
October 02, 2023 08:00 ET
|
PDS Biotechnology Corporation
Study evaluated levels of circulating cell-free HPV DNA (cfDNA) in patients with locally advanced cervical cancer in the IMMUNOCERV Phase 2 clinical trial and patients receiving standard of care (SOC)...
PDS Biotech to Present at the LD Micro Main Event XVI
September 26, 2023 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
September 25, 2023 08:00 ET
|
PDS Biotechnology Corporation
Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a...
PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023 16:05 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies
September 20, 2023 08:00 ET
|
PDS Biotechnology Corporation
PDS0202 (Infectimune® + COBRA influenza antigens) vaccination also prevented illness/weight loss Vaccine protected against replication of the virus in the lungs of ferrets after challenge with the...
PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023
September 13, 2023 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 16:05 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference
September 06, 2023 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting
August 16, 2023 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023 07:30 ET
|
PDS Biotechnology Corporation
Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase 3 VERSATILE-003 trial in the fourth quarter 2023Biomarker data from VERSATILE-002 to be...